Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Medical Innovation

FDA Announces Comprehensive Regenerative Medicine Policy Framework

Washington, DC, November 20, 2017 — The U.S. Food and Drug Administration (FDA) on November 16 announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework – outlined in a suite of four guidance documents – builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products.

Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. Continue reading

Rutgers-Led Research May Lead to New Treatments for Neurodegenerative Diseases and Nerve Injuries

Robert O’Hagan

New Brunswick, NJ, November 13, 2017 — Todd B. Bates reports that inside cells, protein “motors” act like trucks on tiny cellular highways to deliver life-sustaining cargoes.

Now a team led by Rutgers University–New Brunswick researchers has discovered how cells deploy enzymes to place traffic control and “roadway under construction” signs along cellular highways.

“To stay alive and function, every cell in our body needs to transport cargoes to the place they’re needed inside the cell, in the right amount and at the right time,” said Robert O’Hagan, lead author of a new study and assistant research professor in the Human Genetics Institute of New Jersey and the Department of Genetics at Rutgers University–New Brunswick. Continue reading

Robert Wood Johnson Medical School’s New Adult Clinical Research Center Looks to Bring More Clinical Trials to Rutgers

New Brunswick, NJ, November 2, 2017 — Clinical research is essential to preventing and treating diseases, but barriers such as cost, staff and space can create challenges to investigators.

Robert Wood Johnson Medical School’s newly opened Adult Clinical Research Center (CRC) is working to make research more accessible to investigators and convenient for participants, paving the way for increased clinical trials at the university.

The over 11,000-square-foot CRC, adjacent to Robert Wood Johnson University Hospital in New Brunswick, NJ, replaces the previous center, which had operated on the hospital’s third floor for 16 years, and sets the stage for growth. Continue reading

Dr. Jeetu Eswaraka Named Assistant Vice President for Comparative Medicine Resources at Rutgers Office of Research and Economic Development

Dr. Jeetendra (Jeetu) Eswaraka

New Brunswick, NJ, October 26, 2017 — Jeetendra (Jeetu) Eswaraka, DVM, Ph.D., DACLAM, who joined Rutgers University’s Office of Research and Economic Development (ORED) earlier this month as Assistant Vice President for Comparative Medicine Resources, brings a decade and a half of experience leading lab animal research programs in the biopharmaceutical industry.

“I am excited to welcome Jeetu to ORED and Rutgers, and look forward to strengthening and streamlining our operations to be of greater service to the Rutgers research community,” said Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President for Research and Economic Development at Rutgers University. Continue reading

Princeton University Scientists Demonstrate Path to Linking the Genome to Healthy Tissues and Disease

Dr. Barbara Engelhardt

Princeton, NJ, October 25, 2017 — Rachel Nuwer reports that our genomes help to determine who we are — the countless variations between individuals that encode the complexity of tissues and functions throughout the body.

Since scientists first decoded a draft of the human genome more than 15 years ago, many questions have lingered, two of which have been addressed in a major new study co-led by a Princeton University computer scientist:

  • Is it possible, despite the complexity of billions of bits of genetic information and their variations between people, to develop a mechanistic model for how healthy bodies function?
  • Furthermore, can this model be used to understand how certain diseases emerge?

On Oct. 11, scientists came the closest yet to delivering an answer of “yes.” Continue reading

3-D Printing Advances Make the Technology More Useful for Surgery, Implants, Creating Drugs

New York, NY, October 25, 2017 — Aili McConnon reported in The Wall Street Journal that Mayo Clinic is part of a web of organizations racing to find ways to use 3-D printing to improve health care.

Some research institutions, including the Mayo Clinic, have set up on-site printing labs in partnership with such makers of 3-D printers as Stratasys, 3D Systems and Formlabs.

McConnon reports that General Electric Co. and Johnson & Johnson are diving in, too, with GE focused on 3-D printers and translating images from various sources into 3-D objects, and J&J focused on developing a range of materials that can be used as “ink” to print customized objects. Continue reading

Princeton Neuroscience Institute Join with 19 Other Laboratories to Create Virtual Mega-Laboratory; Aims to Probe the Brain’s Deepest Secrets

Princeton, NJ, October 23, 2017Princeton Neuroscience Institute researchers are joining with scientists from 19 other laboratories around the world to create the $15 million International Brain Laboratory (IBL).

Two Princeton neuroscience labs — led by Jonathan Pillow and Ilana Witten — are joining forces with researchers from Europe and the United States to crack the code on how the brain makes choices, by studying the activity and interactions between individual neurons across its different areas.

IBL researchers come from the United States, Great Britain, Portugal, France and Switzerland. Continue reading

NIH Accelerates the Use of Genomics Sequencing in Clinical Care

Bethesda, MD, October 13, 2017 — The National Institutes of Health (NIH) on August 8 announced it is awarding $18.9 million towards research that aims to accelerate the use of genome sequencing in clinical care.

The new awards will generate innovative approaches and best practices to ensure that the effectiveness of genomic medicine can be applied to all individuals and groups, including diverse and underserved populations, and in healthcare settings that extend beyond academic medical centers. Continue reading

PhRMA Announces 2017 Research & Hope Award Honorees; Releases ‘Medicines in Development for Mental Illnesses Report’

Washington, DC, October 11, 2017 — As part of Mental Health Awareness Week, Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday announced it is recognizing and honoring five individuals who are working tirelessly to advocate for patients, fight stigma surrounding mental illnesses and advance research at our 2017 Research & Hope Awards.

In addition, PhRMA said that America’s biopharmaceutical companies are committed to alleviating the considerable burden of mental illness and bringing cutting-edge medicines and new treatments to patients.

According to a new report — “Medicines in Development for Mental Illnesses 2017 Report” — released on October 10, there are more than 140 medicines in development to treat mental illnesses such as anxiety, depression, schizophrenia and more. Continue reading

Hackensack University Medical Center Foundation Receives Donation from Celgene to Advance Multiple Myeloma Research at John Theurer Cancer Center

Former Roche campus to be new Seton Hall-Hackensack Meridian School of Medicine

Hackensack, NJ, October 11, 2017 — The Hackensack University Medical Center Foundation announced on October 5 that it has received a substantial donation from Celgene Corporation to advance multiple myeloma research and transformational medicine that improve patient outcomes at Hackensack Meridian Health–John Theurer Cancer Center.

Supported by Celgene, a global biopharmaceutical leader in the discovery, development and delivery of treatment for diseases like multiple myeloma (MM), funds will help to establish the Multiple Myeloma Institute (MMI) — a leading-edge research facility at the Seton Hall-Hackensack Meridian School of Medicine scheduled to open in 2018.

Celgene and John Theurer Cancer Center are accomplished leaders in developing novel therapies for patients with multiple myeloma. Continue reading